Actualités sur Medicale

Daiichi Sankyo Europe GmbH

Daiichi Sankyo Europe and Esperion Announce Validation of the Marketing Authorisation Application (MAA) for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet

Munich and Ann Arbor, Michigan (ots/PRNewswire) - - Application is based on results of a robust development programme, which demonstrated that bempedoic acid was well tolerated and efficacious for chronic use - Bempedoic acid is a first-in-class, oral, once-daily ATP Citrate Lyase (ACL) inhibitor that reduces ...

Primex Pharmaceuticals

Primex Pharmaceuticals and POA Pharma Sign a Strategic Partnership to Commercialise OZALIN in the Nordic Region

Gothenburg, Sweden and Zug, Switzerland (ots/PRNewswire) - POA Pharma Scandinavia AB, a market-oriented Boutique Healthcare Company, working in close contact with healthcare organizations, professionals and hospitals in Nordic countries and Primex Pharmaceuticals AG, an innovative Anaesthesia pharmaceutical company, ...

Novasep

Novasep Announces the Success of Its Consent Solicitation Extending the Maturity of Its Notes

Lyon, France (ots/PRNewswire) - - All resolutions were approved by 100% of the participating Noteholders and C Warrantholders - Noteholders representing 99.9% of total outstanding principal amount participated Novasep Holding S.A.S ("Novasep"), a leading supplier of services and technologies for the life sciences industry, is pleased to announce that the consent ...

Alvogen

Alvogen Launches Generic Equivalent to Suboxone® (Buprenorphine/Naloxone) Sublingual Film

Pine Brook, New Jersey (ots/PRNewswire) - Global pharmaceutical company, Alvogen, has launched its generic equivalent to Suboxone® sublingual film (buprenorphine hydrochloride/naloxone hydrochloride) in the U.S., which will be available in 2mg/0.5 mg, 4mg/1mg, 8 mg/2mg, and 12 mg/3mg strengths. The launch took ...

Merck Healthcare Germany GmbH

Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine

Not intended for US, Canada and UK-based media Darmstadt, Germany and New York (ots/PRNewswire) - - JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio of 0.69 in patients regardless of PD-L1 expression - US FDA has granted Priority Review to BAVENCIO plus INLYTA for ...

Merck Healthcare Germany GmbH

FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma

Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for BAVENCIO® (avelumab) in ...

Merck Healthcare Germany GmbH

Merck to Expand US Biopharmaceutical R&D Facility to Advance Innovative Clinical Pipeline

Darmstadt, Germany (ots/PRNewswire) - Not intended for US, Canada or UK-based media Merck to Expand US Biopharmaceutical R&D Facility to Advance Innovative Clinical Pipeline - Merck investing $70 million in U.S. Research & Development Hub - Expansion of R&D footprint to accelerate science and innovation in Oncology, ...

CartiHeal (2009) Ltd.

CartiHeal Performs First Agili-C(TM) Cartilage Repair Implantation Procedures at Missouri Orthopaedic Institute

Four patients enrolled and operated on by sports medicine surgeon Dr. Seth L. Sherman, MD Kfar Saba, Israel (ots/PRNewswire) - Seth L. Sherman, MD, a sports medicine orthopaedic surgeon at Missouri Orthopaedic Institute, recently became one of the first American surgeons to enroll patients in a clinical research ...

Merck Healthcare Germany GmbH

Merck and GSK Announce Global Alliance to Jointly Develop and Commercialize M7824, a Novel Immunotherapy with Potential in Multiple Difficult-to-Treat Cancers

Not intended for US, Canada or UK-based media Darmstadt, Germany (ots/PRNewswire) - - Eight high priority immuno-oncology clinical development studies ongoing or expected to commence in 2019, including studies in non-small cell lung and biliary tract cancers - Merck will receive an upfront payment of EUR300 million ...

ForaCare Suisse AG

2

ForaCare Suisse AG forms service-oriented partnership with B. Braun

Kanabo Research

Lights Out for Insomnia: New Kanabo Research Study Offers Encouraging Results

Tel Aviv, Israel (ots/PRNewswire) - Kanabo Research (http://www.kanaboresearch.com) is proud to present the promising results of its pre-clinical trial, which brings the company one step closer to providing a safe remedy for insomnia and other sleep disorders, without the risk of dependency or the possibility of an overdose. (Photo: ...

Hovione

Hovione Issues $50 Million Bond

Lisbon (ots/PRNewswire) - Hovione has issued a bond of $50 million US dollars maturing in 2033. (Logo: https://mma.prnewswire.com/media/813604/Hovione_Logo.jpg ) The bond was arranged and subscribed by Banco BPI, S.A.. According to António Almeida, Hovione's CFO, "we issued this bond to strengthen our balance sheet as we embark in a new phase of significant capital expansion. We issued a USD denominated bond because the majority of our sales is in the USA". The bond is ...

Zentiva

Zentiva Strengthens European Generic Footprint With Prague Manufacturing Site Investment

Prague (ots/PRNewswire) - Zentiva is investing EUR 30 million to maximize its manufacturing site capabilities in Prague. The investment further strengthens Zentiva's manufacturing footprint and is part of a broader ambition to become the champion of generics in Europe. (Logo: https://mma.prnewswire.com/media/788903/Zentiva_Logo.jpg ) Thomas Koene, Head of Industrial ...

Merck Healthcare Germany GmbH

Merck Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors

Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media - Exclusive license grants Vertex one clinical and one pre-clinical DNA-PK inhibitor for use in gene-editing applications in six specific genetic disease areas - Merck retains the rights to both compounds in all other disease areas, including oncology - Merck retains the rights to utilize and ...

Philogen

Philogen Announces Collaboration With Celgene

Siena, Italy (ots/PRNewswire) - Philogen S.p.A. (a privately-owned company) today announced that they have entered into a collaboration and license agreement with Celgene, to discover and develop a new class of immunomodulatory therapeutics. (Logo: https://mma.prnewswire.com/media/811555/Philogen_Logo.jpg ) "We are extremely pleased to establish a new collaboration with Celgene, a leader in the discovery and development ...

Philogen

Philogen Announces Collaboration

Siena, Italy (ots/PRNewswire) - Philogen S.p.A. (a privately-owned company) today announced that they have entered into a collaboration and license agreement with Novartis to discover and develop a new class of immunomodulatory therapeutics. (Logo: https://mma.prnewswire.com/media/811555/Philogen_Logo.jpg ) "We are extremely pleased to establish a new collaboration with Novartis, a leader in the discovery and development of therapies for cancer patients," commented Dr. ...

Philogen

Philogen Announces Drug Discovery Collaboration With Johnson & Johnson Innovation

Siena, Italy (ots/PRNewswire) - Philogen S.p.A., a privately-owned biotechnology company, today announced through its wholly-owned Swiss subsidiary, Philochem AG, a collaboration agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover new small molecule-based therapeutics utilizing Philochem's novel ...

Medasense Biometrics Ltd

Medasense Announces Compatibility with Philips IntelliVue Patient Monitors

Ramat Gan, Israel (ots/PRNewswire) - Medasense Biometrics Ltd., developer of the physiological pain-response monitoring technology (NOL® -- the Nociception Level Index), now supports Philips IntelliVue Patient Monitors for anesthesia and critical care monitoring. (Photo: https://mma.prnewswire.com/media/805789/Medasense_PMD_200_Monitor.jpg ) Commercially available in ...

Debiopharm International SA

Debiopharm Group regains the commercial rights to Trelstar® (Triptorelin pamoate) and looks for new partners in North America

Lausanne, Switzerland (ots) - Debiopharm and Allergan agree to transition the rights to commercialize Trelstar to new licensees. Debiopharm is in advanced discussion with a potential partner in Canada and is engaged in a bidding process for US rights. Debiopharm Group(TM) (Debiopharm - www.debiopharm.com), a ...

Daiichi Sankyo Europe GmbH

Daiichi Sankyo Europe Enters into European Licensing Agreement with Esperion for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet

Munich (ots/PRNewswire) - - Daiichi Sankyo Europe will market oral bempedoic acid and bempedoic acid / ezetimibe combination tablet in the European Economic Area and Switzerland - Bempedoic acid is a first-in-class, oral, once-daily ATP Citrate Lyase (ACL) inhibitor that reduces cholesterol and fatty acid synthesis ...

NEMIS TECHNOLOGIES AG

NEMIS Technologies Ltd. Successfully Closes First Seed Financing Round / Swiss Diagnostic Startup Closes Seed Financing Round of CHF 3 Million Within the First Year

Sophia Genetics

SOPHiA GENETICS Raises $77 Million to Accelerate the Democratization of Data-Driven Medicine

San Francisco (ots/PRNewswire) - SOPHiA GENETICS, a leading health tech company, announced today the closing of a $77 million investment round to accelerate the democratization of Data-Driven Medicine. The round was led by Generation Investment Management, a pioneer of sustainable investing, with offices in London and San Francisco. Generation were joined by Idinvest ...

ProBioGen AG

ProBioGen's GlymaxX® ADCC Enhancement Technology Used by Betta Pharmaceuticals

Berlin (ots/PRNewswire) - Bispecific Antibody for Cancer Treatment Optimized by GlymaxX® Technology ProBioGen AG, a premier service & technology provider for complex therapeutic antibodies and glycoproteins, announced today that the company achieved an undisclosed milestone payment from Merus N.V. (Nasdaq: MRUS) based on Merus' grant of an exclusive license to ...

NORGINE B.V. and KOREA PHARMA CO., LTD.

NORGINE B.V. and KOREA PHARMA CO., LTD. Enter Into Exclusive Licence Agreement for the Commercialisation of PLENVU® in the Republic of Korea

Amsterdam and Seoul, South Korea (ots/PRNewswire) - - Norgine to receive a significant upfront payment and undisclosed sums in sales milestones along with double-digit percentage royalties - Norgine retains full commercial rights to PLENVU® in all unlicensed countries NORGINE B.V. (Norgine), a leading European ...

Merck Healthcare Germany GmbH

Merck and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer

Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced that data from a planned interim analysis of the Phase III JAVELIN Ovarian 100 study of avelumab* did not support the study's initial hypothesis, and therefore the ...

G&G Biotechnology BV

POLYTECH Health & Aesthetics GmbH - Quality Made in Germany Pays Off: CE Approval For Breast Implants From One of the International Leading Companies Currently Confirmed

Dieburg, Germany (ots/PRNewswire) - On December 18, 2018, POLYTECH sold the three millionth implant since its establishment in 1986. The company is the only German manufacturer and present in over 75 countries worldwide. All implants are manufactured in the company's own production facilities in Dieburg near ...

Merck Healthcare Germany GmbH

Merck Announces EMA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer

Darmstadt, Germany (ots/PRNewswire) - The information contained is not intended for distribution in the USA, Canada or the UK - European Medicine Agency (EMA) grants M7824, an investigational bifunctional immunotherapy, orphan drug designation in biliary tract cancer (BTC) - EMA orphan drug designation for M7824 in ...

Merck Healthcare Germany GmbH

Merck Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon

Darmstadt, Germany (ots/PRNewswire) - Not intended for distribution in the USA, Canada or UK - Agreement enables Merck to maintain an investment in the rapidly advancing oncology field of CAR-T, while focusing its R&D efforts - Intrexon to issue Merck $150 million of Intrexon stock and a $25 million convertible note; Intrexon to receive a $25 million cash investment ...

Merck Healthcare Germany GmbH

Merck Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer

Darmstadt, Germany (ots/PRNewswire) - The information contained is not intended for distribution in the USA, Canada or the UK - FDA grants M7824, an investigational bifunctional immunotherapy, orphan drug designation in biliary tract cancer - First regulatory designation for M7824 following recent presentation of ...

Merck Healthcare Germany GmbH

Merck in Agreement With Cyclica for AI-augmented Screening Platform to Expand Research Capabilities

Darmstadt, Germany (ots/PRNewswire) - Not intended for distribution in the USA, Canada or UK - Agreement to screen discovery and early development compounds using artificial intelligence and computational biophysics - Cloud-based in silico platform that screens small molecules to determine polypharmacological ...